Dana-Farber Cancer Institute researchers unveiled a platform for systematically discovering molecular glue degraders, aiming to broaden the druggable space beyond conventional inhibitor targets. The work, published in Nature, describes identification of the first metabolically activated molecular glue degrader through a mechanism involving glutathionylation. The platform uses a discovery workflow that fixes a subset of E3 ligases and screens compounds in cellular lysate to find glue-like interactions. Investigators highlighted that current clinical protein degraders rely on a limited fraction of human E3 ligases, leaving room for expansion. The metabolically activated feature suggests molecular glues may depend on cellular context, which could influence dosing strategies and which tumor types are most responsive.